Inivata Ltd - Product Pipeline Analysis, 2023 Update

Summary


Inivata Ltd (Inivata), a subsidiary of NeoGenomics Inc., is a cancer genomics company that harnesses liquid biopsy platforms to enhance personalized healthcare in oncology. The company’s product portfolio includes InVisionFirst – Lung, which offers advanced sequencing technology to detect copy number variants, single nucleotide variants, insertions and deletions, and structural variants in selected genes from DNA isolated from plasma samples from patients with non-small cell lung cancer; and InVisionSeq test. Inivata collaborates with industry and academic researchers to develop new clinical applications for liquid biopsy and ctDNA analysis. The company operates across the UK and the US. Inivata is headquartered in Cambridge, Cambridgeshire, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Inivata Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company


Inivata Ltd Company Overview
Inivata Ltd Company Snapshot
Inivata Ltd Pipeline Products and Ongoing Clinical Trials Overview
Inivata Ltd – Pipeline Analysis Overview
Inivata Ltd - Key Facts
Inivata Ltd - Major Products and Services
Inivata Ltd Pipeline Products by Development Stage
Inivata Ltd Ongoing Clinical Trials by Trial Status
Inivata Ltd Pipeline Products Overview
InVision ctDNA Assay - EGFR-Mutant NSCLC
InVision ctDNA Assay - EGFR-Mutant NSCLC Product Overview
InVision ctDNA Assay - Metastatic Breast Cancer
InVision ctDNA Assay - Metastatic Breast Cancer Product Overview
InVision ctDNA Assay - NSCLC
InVision ctDNA Assay - NSCLC Product Overview
InVision ctDNA Assay - Pancreatic Cancer
InVision ctDNA Assay - Pancreatic Cancer Product Overview
InVision ctDNA Assay - Stage III/IV NSCLC
InVision ctDNA Assay - Stage III/IV NSCLC Product Overview
RaDaR Assay
RaDaR Assay Product Overview
RaDaR Assay Clinical Trial
Inivata Ltd - Key Competitors
Inivata Ltd - Key Employees
Inivata Ltd - Locations And Subsidiaries
Head Office
Recent Developments
Inivata Ltd, Recent Developments
Dec 27, 2023: Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
Dec 05, 2023: NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
Jul 27, 2023: NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
Jun 15, 2023: Neogenomics’ RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
Jun 05, 2023: NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
May 30, 2023: NeoGenomics to showcase the transformational impact of RaDaR assay for molecular residual disease and recurrence monitoring at ASCO
Apr 06, 2023: NeoGenomics to share nine abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023
Mar 16, 2023: NeoGenomics announces commercial availability of the RaDaR Molecular Residual Disease Test
Feb 06, 2023: RaDaR(R) assay demonstrates clinical potential for helping Oncologists determine whether or not muscle-invasive bladder cancer patients undergo radical surgery
Nov 21, 2022: RaDaR(R) Assay demonstrates clinical potential for detecting disease recurrence across all types of early breast cancer, including triple negative disease
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: Inivata Ltd Pipeline Products and Ongoing Clinical Trials Overview
Table 2: Inivata Ltd Pipeline Products by Equipment Type
Table 3: Inivata Ltd Pipeline Products by Indication
Table 4: Inivata Ltd, Key Facts
Table 5: Inivata Ltd, Major Products and Services
Table 6: Inivata Ltd Number of Pipeline Products by Development Stage
Table 7: Inivata Ltd Pipeline Products Summary by Development Stage
Table 8: Inivata Ltd Ongoing Clinical Trials by Trial Status
Table 9: Inivata Ltd Ongoing Clinical Trials Summary
Table 10: InVision ctDNA Assay - EGFR-Mutant NSCLC - Product Status
Table 11: InVision ctDNA Assay - EGFR-Mutant NSCLC - Product Description
Table 12: InVision ctDNA Assay - Metastatic Breast Cancer - Product Status
Table 13: InVision ctDNA Assay - Metastatic Breast Cancer - Product Description
Table 14: InVision ctDNA Assay - NSCLC - Product Status
Table 15: InVision ctDNA Assay - NSCLC - Product Description
Table 16: InVision ctDNA Assay - Pancreatic Cancer - Product Status
Table 17: InVision ctDNA Assay - Pancreatic Cancer - Product Description
Table 18: InVision ctDNA Assay - Stage III/IV NSCLC - Product Status
Table 19: InVision ctDNA Assay - Stage III/IV NSCLC - Product Description
Table 20: RaDaR Assay - Product Status
Table 21: RaDaR Assay - Product Description
Table 22: RaDaR Assay - Liquid Biopsy for Minimal Residual Disease Detection in Head and Necksquamous Cell Carcinoma (LIONESS) Study
Table 23: RaDaR Assay - SURVIVE (Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer) - a Partially Double-blinded, Multi-center, Randomized, Controlled Superiority Study
Table 24: Inivata Ltd, Key Employees
Table 25: Glossary
List of Figures
Figure 1: Inivata Ltd Pipeline Products by Equipment Type
Figure 2: Inivata Ltd Pipeline Products by Development Stage
Figure 3: Inivata Ltd Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings